Related Experiment Video
Updated: Apr 12, 2026
Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
Published on: May 18, 2018
Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy
Md Selim Ahmed1, Se Eun Byeon1, Yideul Jeong1
1Department of Biological Science; Sungkyunkwan University ; Suwon, Gyounggi-do, Republic of Korea.
Insights
Dab2 protein negatively regulates dendritic cell (DC) immunogenicity. Silencing Dab2 enhances DC function and improves DC vaccine efficacy against tumors, suggesting Dab2 as a therapeutic target.
Area of Science:
- Immunology
- Cell Biology
- Molecular Biology
Background:
- Dab2 is an adapter protein regulating cellular processes like signaling and endocytosis.
- Dab2 is crucial for regulatory T (Treg) cell function and is a Foxp3 target gene.
- The role of Dab2 in dendritic cells (DCs) was previously undescribed.
Purpose of the Study:
- To investigate Dab2 expression and function in dendritic cells.
- To determine the regulatory mechanisms of Dab2 expression in DCs.
- To evaluate the impact of Dab2 modulation on DC immunogenicity and vaccine efficacy.
Main Methods:
- Induction of Dab2 during mouse bone marrow-derived DC (BMDC) and human monocyte-derived DC (MoDC) development.
- Analysis of signaling pathways (STAT5, PI3K/Akt) involved in Dab2 expression.
- Dab2 silencing and overexpression in DCs.
- Assessment of DC function (antigen uptake, migration, T cell stimulation).
- Evaluation of DC vaccine efficacy in a tumor model.
Main Results:
- Dab2 expression is induced during DC development and present in splenic DCs.
- PI3K/Akt signaling, STAT5, Foxp3, and hnRNPE1 are required for Dab2 expression.
- Dab2 silencing enhanced IL-12 and IL-6 production, and improved DC antigen uptake, migration, and T cell stimulation.
- Dab2-silenced DCs generated potent CTL responses and inhibited tumor growth more effectively.
- Dab2 overexpression reduced DC vaccine efficacy.
Conclusions:
- Dab2 acts as an intrinsic negative regulator of DC immunogenicity.
- Modulating Dab2 expression can enhance DC vaccine efficacy for cancer immunotherapy.
- Dab2 represents a potential molecular target for improving DC-based vaccines.
Abstract:
Dab2 is an adapter protein involved in receptor-mediated signaling, endocytosis, cell adhesion, hematopoietic cell differentiation, and angiogenesis. It plays a pivotal role in controlling cellular homeostasis. In the immune system, the Dab2 is a Foxp3 target gene and is required for regulatory T (Treg) cell function. Dab2 expression and its biological function in dendritic cells (DCs) have not been described. In this study, we found that Dab2 was significantly induced during the development of mouse bone marrow (BM)-derived DCs (BMDCs) and human monocyte-derived DCs (MoDCs). Even in a steady state, Dab2 was expressed in mouse splenic DCs (spDCs). STAT5 activation, Foxp3 expression, and hnRNPE1 activation mediated by PI3K/Akt signaling were required for Dab2 expression during GM-CSF-derived BMDC development regardless of TGF-β signaling. Dab2-silencing was accompanied by enhanced IL-12 and IL-6 expression, and an improved capacity of DC for antigen uptake, migration and T cell stimulation, which generated strong CTL in vaccinated mice. Vaccination with Dab2-silenced DCs inhibited tumor growth more effectively than did vaccination with wild type DCs. Dab2-overexpression abrogated the efficacy of the DC vaccine in DC-based tumor immunotherapy. These data strongly suggest that Dab2 might be an intrinsic negative regulator of the immunogenicity of DCs, thus might be an attractive molecular target to improve DC vaccine efficacy.
